Moleculin Biotech, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 16, 2026. The filing is intended to satisfy the registrant’s reporting obligations under Section 13 or 15(d) of the Securities Exchange Act of 1934.
The company disclosed that it is furnishing information pursuant to Regulation FD Disclosure. Specifically, Moleculin Biotech is providing an attached corporate presentation dated October 16, 2026. This presentation has been posted to the company’s website and is included in the filing as Exhibit 99.1.
The company noted that the information contained in Item 7.01 of this report, including the attached presentation, is being furnished and shall not be “filed” for the purposes of the Securities Exchange Act of 1934 or the Securities Act of 1933, unless specifically identified therein as being incorporated by reference.
The filing also includes the cover page of the Form 8-K, formatted as an Interactive Data File (Inline XBRL document), and the signature of Jonathan P. Foster.
